Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $16

Benzinga Newsdesk www.benzinga.com Positive 65.5%

Neg 0% Neu 0% Pos 65.5%

Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $14 to $16.